Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Cut to $750.00 by Analysts at Citigroup

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price lowered by Citigroup from $795.00 to $750.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a neutral rating on the biopharmaceutical company’s stock.

A number of other research analysts have also issued reports on REGN. Wells Fargo & Company dropped their target price on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a report on Friday, January 10th. Cantor Fitzgerald restated a “neutral” rating and issued a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. Evercore ISI cut their price target on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Royal Bank of Canada lowered their price objective on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Finally, Barclays cut their target price on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $1,004.57.

Regeneron Pharmaceuticals Trading Down 0.6 %

NASDAQ REGN opened at $683.08 on Tuesday. Regeneron Pharmaceuticals has a one year low of $666.25 and a one year high of $1,211.20. The firm has a market cap of $75.06 billion, a PE ratio of 16.90, a P/E/G ratio of 1.59 and a beta of 0.10. The firm’s fifty day moving average is $723.36 and its two-hundred day moving average is $928.61. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several hedge funds have recently bought and sold shares of REGN. Creative Planning grew its holdings in shares of Regeneron Pharmaceuticals by 11.5% during the second quarter. Creative Planning now owns 9,615 shares of the biopharmaceutical company’s stock worth $10,106,000 after buying an additional 991 shares in the last quarter. Magnolia Capital Advisors LLC acquired a new stake in Regeneron Pharmaceuticals during the second quarter worth approximately $236,000. NewEdge Advisors LLC grew its stake in Regeneron Pharmaceuticals by 6.3% in the 2nd quarter. NewEdge Advisors LLC now owns 4,368 shares of the biopharmaceutical company’s stock worth $4,591,000 after acquiring an additional 260 shares during the period. Northwestern Mutual Wealth Management Co. raised its holdings in Regeneron Pharmaceuticals by 16.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 3,821 shares of the biopharmaceutical company’s stock valued at $4,016,000 after acquiring an additional 536 shares during the last quarter. Finally, B. Riley Wealth Advisors Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 8.0% during the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 1,086 shares of the biopharmaceutical company’s stock worth $1,142,000 after purchasing an additional 80 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.